ArticleGastroenterology research2025
Article in Gastroenterology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Background: Methods: The study comprised 21 patients (11 men) who completed a questionnaire about age, number of years with hemochromatosis, and at least 10 consecutive blood sample results, including ferritin, iron, transferrin and transferrin saturation (TSAT). The control group consisted of 958 persons (441 men). Results: The findings were comparable in both genders: 1) All but one patient had significantly lower transferrin levels than controls; 2) Serum iron and ferritin showed negative correlations with transferrin; 3) TSAT displayed strong negative correlations with transferrin; 4) Positive correlations were present between iron and ferritin, iron and TSAT, and ferritin and TSAT. Conclusions: Hemochromatosis patients had lower transferrin levels than controls, contributing to a higher TSAT; the explanation for this remains unsolved. Patients displayed negative correlations between iron and ferritin vs. transferrin, as well as negative correlations between TSAT and transferrin, suggesting that high TSAT levels may accelerate the degradation of transferrin. In
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.